Drug monographs: bosutinib and regorafenib. - Wikidata - wikimedia - TriplyDB

Drug monographs: bosutinib and regorafenib.

Drug monographs: bosutinib and regorafenib.

http://www.wikidata.org/entity/Q37340111

about

Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer Regorafenib in the treatment of colorectal cancer.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.

P2860

Q33944599-AC185C4D-841E-4003-86ED-B15FF3C306F2 Q38630817-C34A7EF6-EED7-4302-ACB8-B4226F400420 Q38937228-791598DA-4F52-4B61-9FD0-398AB3E4AC3F

P2860

Drug monographs: bosutinib and regorafenib.

http://www.wikidata.org/entity/Q37340111

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Drug monographs: bosutinib and regorafenib.

@en

Drug monographs: bosutinib and regorafenib.

@nl

type

label

Drug monographs: bosutinib and regorafenib.

@en

Drug monographs: bosutinib and regorafenib.

@nl

prefLabel

Drug monographs: bosutinib and regorafenib.

@en

Drug monographs: bosutinib and regorafenib.

@nl

P1433

Q37340111-BCB63FC6-745D-452F-AB9E-72994E6E3167

P1476

Q37340111-60325404-6C5A-4F7E-AD85-ACB0B83FC04F

P2093

Q37340111-4627A14C-9946-4362-A483-86BD67091BAB

Q37340111-AE7166CF-F6EB-4961-8E7F-D048600A99D3

P2860

Q37340111-121E1BFB-B19C-4A6E-B38B-1BBF354D3AF0

Q37340111-2712FF4B-2990-4CB8-9A3A-3DBEA1F2A7DA

Q37340111-29AD4188-1AD1-4CB1-A76E-47F8D36D0794

Q37340111-330DD1C0-7339-4AB3-8AB2-73F17ED4D7C6

Q37340111-3FF2D93E-A550-45AF-AD32-9BA6A0FA62A2

Q37340111-537DF95E-D584-40D9-9029-C5DB717F8BE8

Q37340111-643CC6E7-5368-4576-872B-F1FE3B902556

Q37340111-AF1173BD-1224-4F89-8958-E21AFE610BC9

Q37340111-BC862324-7FD9-4A1E-881B-50C69760144A

Q37340111-F6A58A91-2717-4B5E-A094-520FF6F19D0F

P304

Q37340111-B2F4C86B-5B85-445F-BB4B-EDAC94D1864B

P31

Q37340111-739B5B43-B9CE-4783-9DF1-FBE5AAEB06B6

P356

Q37340111-D590DCCB-FDC4-49A5-A273-7982669AC952

P433

Q37340111-37FA6537-0FF6-438E-AA72-04E65B7ACA52

P478

Q37340111-1FA6C409-FFF4-489A-990E-32F7C2D90095

P577

Q37340111-BEB0395E-8778-42E8-880B-3557E914BF23

P698

Q37340111-26596F8C-E128-4E8C-B60B-4A292098671F

P932

Q37340111-0E63B831-CFB4-4C12-AFE0-ED7C8015C006

P356

P1433

Hospital pharmacy

P1476

Drug monographs: bosutinib and regorafenib.

@en

P2093

Dominic A Solimando

http://www.w3.org/2001/XMLSchema#string

J Aubrey Waddell

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.

A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.

A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy

P304

190-194

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1310/HPJ4803-190

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24421459

http://www.w3.org/2001/XMLSchema#string

P932

3839511

http://www.w3.org/2001/XMLSchema#string